micro-community-banner
 
Profile Image
  • Saved
Urinary Glycosaminoglycans are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women

Urinary Glycosaminoglycans are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882061/

Version 1. bioRxiv. Preprint. 2023 Jan 12. It has not yet been peer reviewed by a journal. The National Library of Medicine is running a pilot to include preprints that...

Conclusion: Urinary GAGs are associated with rUTI disease state and urobiome ecology. We hypothesize that urogenital dysbiosis is also associated with changes in the urothelial GAG layer. This hypothesis is evidenced by our observations of negative correlations between urinary CS and taxa known to be signatures of dysbiosis in the vagina. The...

Profile Image
  • Saved

Conclusion: Although FCCs are most common in premenopausal women or postmenopausal women on hormone replacement therapy, they may also rarely present in postmenopausal women, not on hormone replacement therapy. However, due to the overlapping radiographic findings of FCCs and malignancy, any new finding in the postmenopausal patient should...

Profile Image
  • Saved
Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea–based retrospective cohort study

Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea–based retrospective cohort study

Source : https://journals.lww.com/menopausejournal/Abstract/9900/Menopausal_hormone_therapy_and_the_risk_of_type_2.163.aspx

ether MHT, which is currently widely prescribed, increases the risk of T2DM. Method We performed a retrospective cohort study based on national health insurance data and cancer screening data from...

Conclusion: MHT, including tibolone, which is currently the most prescribed agent, increased the risk of T2DM; however, CEPM did not increase the risk of T2DM. Only tibolone increased the risk of T2DM in participants older than 70 years.

Profile Image
  • Saved
Antidepressant Use to Treat Menopausal Vasomotor Symptoms

It is estimated that close to 40% of the world's 1.2 billion women will be post-menopausal or menopausal by 2030. That's nearly 50 million women and, among those, ~60-70% are likely to suffer from menopausal symptoms. Although hormone therapy (HT) is suggested for curtailing both vasomotor symptoms and mood disturbances, HT treatment continues to be controversial. Aside from breast cancer and cardiovascular concerns, research shows that HT itself might also increase the risk of depression.

In a recent discussion among OB-GYNs and primary care clinicians, about half stated they treat menopausal vasomotor symptoms with antidepressants such as SSRIs, SNRIs, and bupropion. While there was agreement that the treatment may not address all of the symptoms, research has confirmed that antidepressants are effective in treating both depression and vasomotor symptoms shortly before, during, and after menopause.

Which antidepressant(s) do you find most effective for the treatment of menopause? Have you observed whether these are the same antidepressants that work in younger women for premenstrual dysphoric disorder?

Profile Image
  • 2yr
    I would consider using Paroxetine for treatment of VMS if there is contraindications to use of hormonal Rx, risk of thromboembolism and breast cancer with the use of Estrogen, change Show More
  • 2yr
    SSRI’s as a class all work excellently in their relief of VMS of menopause. The longest acting, best studied, and most economical in the class is fluoxetine. A simple daily Show More

Show More Comments

  • Saved
Antidepressant Use to Treat Menopausal Vasomotor Symptoms

It is estimated that close to 40% of the world's 1.2 billion women will be post-menopausal or menopausal by 2030. That's nearly 50 million women and, among those, ~60-70% are likely to suffer from menopausal symptoms. Although hormone therapy (HT) is suggested for curtailing both vasomotor symptoms and mood disturbances, HT treatment continues to be controversial. Aside from breast cancer and cardiovascular concerns, research shows that HT itself might also increase the risk of depression.

In a recent discussion among OB-GYNs and primary care clinicians, about half stated they treat menopausal vasomotor symptoms with antidepressants such as SSRIs, SNRIs, and bupropion. While there was agreement that the treatment may not address all of the symptoms, research has confirmed that antidepressants are effective in treating both depression and vasomotor symptoms shortly before, during, and after menopause.

Which antidepressant(s) do you find most effective for the treatment of menopause? Have you observed whether these are the same antidepressants that work in younger women for premenstrual dysphoric disorder?

Profile Image
  • 2yr
    I have treated patient with Venlafaxine ER and have had good effect with VMS as well as the benefit of decreased anxiety and depression. I have even have had Show More
  • 2yr
    I have seen good improvement with fluoxetine and paroxetine. Patients on sertraline had shown some side effects. Seen symptoms improve by over 50% in many cases.

Show More Comments